James M. Randall

571 total citations
19 papers, 409 citations indexed

About

James M. Randall is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, James M. Randall has authored 19 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in James M. Randall's work include Cancer Genomics and Diagnostics (5 papers), Prostate Cancer Treatment and Research (5 papers) and Renal cell carcinoma treatment (4 papers). James M. Randall is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Prostate Cancer Treatment and Research (5 papers) and Renal cell carcinoma treatment (4 papers). James M. Randall collaborates with scholars based in United States, Netherlands and India. James M. Randall's co-authors include Razelle Kurzrock, Frederick Millard, Lyudmila Bazhenova, Sandip Pravin Patel, Assuntina G. Sacco, Aaron M. Goodman, Gregory A. Daniels, Emma Ream, Wayne A. Bardwell and Robert A. Figlin and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

James M. Randall

18 papers receiving 404 citations

Peers

James M. Randall

PRM

ONCOL

IMMUN

Giorgia Guaitoli Italy

Jane‐Chloé Trone France

Petr Krivorotko Russia

Joaquina Martínez-Galán Spain

Hongfei Gao China

Aiko Nagayama Japan

Minsig Choi United States

Coralie Moncharmont France

Sheau Wen Lok Australia

Erika Matos Slovenia

Giorgia Guaitoli Italy

James M. Randall

162 ×0.9

PRM

229 ×1.2

ONCOL

121 ×0.8

146 ×1.0

33 ×0.8

IMMUN

Citations per year, relative to James M. Randall James M. Randall (= 1×) peers Giorgia Guaitoli

Countries citing papers authored by James M. Randall

Since Specialization

Citations

This map shows the geographic impact of James M. Randall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Randall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Randall more than expected).

Fields of papers citing papers by James M. Randall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Randall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Randall. The network helps show where James M. Randall may publish in the future.

Co-authorship network of co-authors of James M. Randall

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Randall. A scholar is included among the top collaborators of James M. Randall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Randall. James M. Randall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Zheng, Shuhua, et al.. (2023). Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non‐small cell lung cancer. Thoracic Cancer. 14(23). 2269–2274. 5 indexed citations

Shaya, Justin, Angelo Cabal, James M. Randall, et al.. (2022). The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer. Clinical Genitourinary Cancer. 20(6). 515–523. 15 indexed citations

Pan, Elizabeth, Justin Shaya, Lisa Madlensky, et al.. (2022). Germline alterations among Hispanic men with prostate cancer. Prostate Cancer and Prostatic Diseases. 25(3). 561–567. 4 indexed citations

Shaya, Justin, Angelo Cabal, James M. Randall, et al.. (2021). Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer. Clinical Genitourinary Cancer. 19(6). 564.e1–564.e10. 7 indexed citations

Riviere, Paul, Whitney Sumner, Ajay Sandhu, et al.. (2021). Radiation Recall Pneumonitis After Treatment With Checkpoint Blockade Immunotherapy: A Case Series and Review of Literature. Frontiers in Oncology. 11. 662954–662954. 17 indexed citations

Shaya, Justin, Lisa Madlensky, Frederick Millard, et al.. (2021). Analysis of germline alterations and testing patterns in Hispanic men with prostate cancer.. Journal of Clinical Oncology. 39(6_suppl). 18–18. 1 indexed citations

Shaya, Justin, Aaron Lee, Angelo Cabal, et al.. (2021). The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology. 39(6_suppl). 150–150.

Patel, Sunil, et al.. (2019). Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies. European Urology Focus. 6(1). 17–25. 2 indexed citations

Vitzthum, Lucas K., Reith Sarkar, Rana R. McKay, et al.. (2019). Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy. Journal of the National Comprehensive Cancer Network. 17(12). 1497–1504. 1 indexed citations

10.

Goodman, Aaron M., Gregory A. Daniels, Sandip Pravin Patel, et al.. (2017). Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy. Clinical Cancer Research. 23(19). 5729–5736. 159 indexed citations

11.

Voss, Martin H., Arif Hussain, Nicholas J. Vogelzang, et al.. (2017). A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Annals of Oncology. 28(11). 2754–2760. 66 indexed citations

12.

Patel, Nishant, Jason Woo, Michael A. Liss, et al.. (2016). Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches.. PubMed. 23(2). 8227–33. 12 indexed citations

13.

Hamilton, Zachary, Hak J. Lee, Juan A. Jimènez, et al.. (2016). Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. British Journal of Urology. 118(6). 927–934. 8 indexed citations

14.

Randall, James M., Mark G. Erlander, Cecile Rose T. Vibat, et al.. (2015). Non-Invasive Monitoring of Urinary KRAS Circulating Tumor DNA for Treatment Response and Minimal Residual Disease in Patients with Lung Adenocarcinoma.. Journal of Clinical Oncology. 33(15_suppl). e19092–e19092. 1 indexed citations

15.

Randall, James M., Frederick Millard, & Razelle Kurzrock. (2014). Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer and Metastasis Reviews. 33(4). 1109–1124. 68 indexed citations

16.

Randall, James M., et al.. (2013). Clinic-based depression screening in lung cancer patients using the PHQ-2 and PHQ-9 depression questionnaires: a pilot study. Supportive Care in Cancer. 21(5). 1503–1507. 23 indexed citations

17.

Randall, James M., et al.. (2013). Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer.. PubMed. 5(2). E53–7. 4 indexed citations

18.

Gross, Andrew M., et al.. (2013). Association of methylation of genes in the taurine/hypotaurine pathway with worse prognosis in renal cell carcinoma.. Journal of Clinical Oncology. 31(15_suppl). e15562–e15562. 2 indexed citations

19.

Randall, James M. & Emma Ream. (2005). Hair loss with chemotherapy: at a loss over its management?. European Journal of Cancer Care. 14(3). 223–231. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact